干扰素α-1b雾化吸入治疗小儿手足口病98例疗效分析  

Analysis of Atomized Inhalation of Recombination Human Interferon-α-1b for the Treatment of 98 Patients with Hand, Foot and Mouth Disease

作　　者：陈鸿健[1] 叶宁[1] 于毅[1] 

机构地区：[1]南京医科大学附属南京儿童医院,江苏南京210008

出　　处：《医学临床研究》2013年第7期1302-1303,1306,共3页Journal of Clinical Research

摘　　要：【目的】探讨干扰素α-1b治疗儿童手足口病的疗效及安全性。【方法】将189例儿童手足口病随机分为观察组98例，给予干扰素雾化吸入每日1次，对照组9l倒，给予静眯滴入病毒唑每日1次，疗程均为3d。【结果】观察组的总有效率为93．88％，对照组为60．44％，两组比较差异有显著性（P〈0．01）。观察组在退热时间，手足皮疹及口腔溃疡愈合方面均优于对照组（P〈O．01），观察组未发现明显毒副作用。【结论】干扰素治疗儿童手足口病的疗效明显优于利巴韦林，值得临床上推广应用。[Objective]To explore the efficacy and safety of interferoncclb for the treatment of children with hand, foot and mouth disease. [Methods] Totally 189 children with hand, foot and mouth disease were randomly divided into treatment group（ n = 98） and control group（ n = 91）. The treatment group was given interferonα-lb by atomized inhala- tion once daily, while the control group was given ribavirin by intravenous injection once daily. The treatment course was 3 days. [Results]The total effective rate of treatment group and control group was 93.88% and 60.44% respectively, and there were significant differences between two groups（ P 〈0.01）. The time of temperature decreasing and the skim rash and mouth ulcer healing in treatment group were better than control group（ P 〈0.01）. No obvious side effect was found in treatment group. [Conclusion]The efficacy of interferoncclb for the treatment of children with hand, foot and mouth disease is better than ribavirin. It is worthy of clinical promotion.

关 键 词：手足口病 药物疗法 干扰素Α 投药和剂量 

分 类 号：R725.125.7[医药卫生—儿科]